Cargando…
Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration &l...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818953/ https://www.ncbi.nlm.nih.gov/pubmed/29545953 http://dx.doi.org/10.1155/2018/6027871 |
_version_ | 1783301117840457728 |
---|---|
author | Kim, Ye Ji Lee, Youn Gon Lee, Dong Won Kim, Jae Hui |
author_facet | Kim, Ye Ji Lee, Youn Gon Lee, Dong Won Kim, Jae Hui |
author_sort | Kim, Ye Ji |
collection | PubMed |
description | PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration < 3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared. RESULTS: The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16 ± 0.18) than at the time of diagnosis (0.27 ± 0.18, P = 0.002). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6 ± 17.9 μm) than at baseline (441.4 ± 124.8 μm, P < 0.001). No notable SRT-related complications were observed during the study period. CONCLUSION: The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856. |
format | Online Article Text |
id | pubmed-5818953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58189532018-03-15 Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Kim, Ye Ji Lee, Youn Gon Lee, Dong Won Kim, Jae Hui J Ophthalmol Clinical Study PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration < 3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared. RESULTS: The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16 ± 0.18) than at the time of diagnosis (0.27 ± 0.18, P = 0.002). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6 ± 17.9 μm) than at baseline (441.4 ± 124.8 μm, P < 0.001). No notable SRT-related complications were observed during the study period. CONCLUSION: The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856. Hindawi 2018-02-06 /pmc/articles/PMC5818953/ /pubmed/29545953 http://dx.doi.org/10.1155/2018/6027871 Text en Copyright © 2018 Ye Ji Kim et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Kim, Ye Ji Lee, Youn Gon Lee, Dong Won Kim, Jae Hui Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title | Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title_full | Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title_fullStr | Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title_full_unstemmed | Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title_short | Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients |
title_sort | selective retina therapy with real-time feedback-controlled dosimetry for treating acute idiopathic central serous chorioretinopathy in korean patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818953/ https://www.ncbi.nlm.nih.gov/pubmed/29545953 http://dx.doi.org/10.1155/2018/6027871 |
work_keys_str_mv | AT kimyeji selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients AT leeyoungon selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients AT leedongwon selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients AT kimjaehui selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients |